3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Gastrointestinal Stromal Tumors
3
Colorectal Neoplasms
3
Pancreatic Neoplasms
2
Colonic Neoplasms
2
Choledocholithiasis
2
Carcinoma, Non-Small-Cell Lung
2
Stomach Neoplasms
1
Recurrence
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Polyps
1
Personal Satisfaction
1
Patient Satisfaction
1
Parasomnias
1
Pancreatitis
1
Pain, Postoperative
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Liposarcoma
1
Glioblastoma
1
Diverticulosis, Colonic
1
Choledochal Cyst
1
Cholangitis
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Anxiety Disorders
1
Adenocarcinoma of Lung
1
Interventions
pembrolizumab
3
spartalizumab
2
trametinib
1
tislelizumab
1
palbociclib
1
nazartinib
1
milademetan
1
enzalutamide
1
devimistat
1
dehydroftorafur
1
canakinumab
1
binimetinib
1
bemarituzumab
1
aldesleukin
1
Specimen Handling
1
Pentostatin
1
Midazolam
1
Methods
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Interleukin-2
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Early Intervention, Educational
1
Cyclophosphamide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
Midazolam
×
Gastrointestinal
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled